Overview

A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The study will determine if there are differences in how dacomitinib is absorbed and eliminated between healthy subjects and subjects with mild and moderately impaired hepatic function.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer